Format

Send to

Choose Destination
Med Clin (Barc). 2015 May 21;144(10):457-64. doi: 10.1016/j.medcli.2014.03.023. Epub 2014 Jun 3.

[Neuroepigenetics: Desoxyribonucleic acid methylation in Alzheimer's disease and other dementias].

[Article in Spanish]

Author information

1
Complejo Hospitalario de Navarra, Pamplona, Navarra, España; Navarrabiomed, Pamplona, Navarra, España. Electronic address: tmendioi@navarra.es.
2
Complejo Hospitalario de Navarra, Pamplona, Navarra, España; Navarrabiomed, Pamplona, Navarra, España.
3
Hospital García Orcoyen, Estella, Navarra, España.

Abstract

DNA methylation is an epigenetic mechanism that controls gene expression. In Alzheimer's disease (AD), global DNA hypomethylation of neurons has been described in the human cerebral cortex. Moreover, several variants in the methylation pattern of candidate genes have been identified in brain tissue when comparing AD patients and controls. Specifically, DNA methylation changes have been observed in PSEN1 and APOE, both genes previously being involved in the pathophysiology of AD. In other degenerative dementias, methylation variants have also been described in key genes, such as hypomethylation of the SNCA gene in Parkinson's disease and dementia with Lewy bodies or hypermethylation of the GRN gene promoter in frontotemporal dementia. The finding of aberrant DNA methylation patterns shared by brain tissue and peripheral blood opens the door to use those variants as epigenetic biomarkers in the diagnosis of neurodegenerative diseases.

KEYWORDS:

Alzheimer disease; Demencia; Dementia; Enfermedad de Alzheimer; Epigenetics; Epigenética; Methylation; Metilación

PMID:
24907105
DOI:
10.1016/j.medcli.2014.03.023
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center